Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

被引：6
|
作者：
Guercio, Brendan John [1 ]
Pietzak, Eugene J. [1 ]
Brown, Samantha [1 ]
Chen, Jie-Fu [1 ]
Peters, Vanessa [1 ]
Regazzi, Ashley Marie [1 ]
Aggen, David Henry [1 ]
Donahue, Timothy F. [1 ]
Goh, Alvin C. [1 ]
Cha, Eugene K. [1 ]
Donat, S. Machele [1 ]
Dalbagni, Guido [1 ]
Bochner, Bernard H. [1 ]
Funt, Samuel Aaron [1 ]
Bajorin, Dean F. [1 ]
Iyer, Gopa [1 ]
Ostrovnaya, Irina [1 ]
Al-Ahmadie, Hikmat A. [1 ]
Rosenberg, Jonathan E. [1 ]
Teo, Min Yuen [1 ]
机构：
[1] US Natl Inst Health, Conquer Canc Fdn Amer Soc Clin Oncol, Bristol Myers Squibb, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
498
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).
    Galsky, Matt D.
    Harshman, Lauren Christine
    Crabb, Simon J.
    Wong, Yu-Ning
    Yu, Evan Y.
    Chowdhury, Simon
    Powles, Thomas
    Pal, Sumanta Kumar
    Moshier, Erin L.
    Ladoire, Sylvain
    Hussain, Syed A.
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Recine, Federica
    Berthold, Dominik
    Necchi, Andrea
    Theodore, Christine
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
    Jain, R. K.
    Chatwal, M.
    Chadha, J.
    Oschmann, E.
    Mizelle, S.
    Poehlman, T.
    Fan, W.
    Kim, Y.
    Dhillon, J.
    Wang, X.
    Zhang, J.
    Guevara, J-A.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2024, 35 : S1141 - S1141
  • [33] Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
    Tong, Z.
    Fu, G.
    Zhou, F.
    Liu, X.
    Xue, X.
    Zhang, H.
    Wang, Y.
    Zhu, X.
    Gao, Y.
    Liu, L.
    Bao, X.
    Zheng, Y.
    Fang, W.
    Zhao, P.
    Jin, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1210 - S1210
  • [34] Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Xing, N.
    Han, S.
    Jiang, J.
    Xu, W.
    Shi, B.
    Ping, H.
    Ji, Z.
    Ma, Q.
    Wang, H.
    Chen, S.
    Wang, W.
    Fan, X.
    Zhou, Q.
    Zhang, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S714 - S714
  • [35] Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.
    Funt, Samuel Aaron
    Lattanzi, Michael
    Whiting, Karissa
    Al-Ahmadie, Hikmat A.
    Quinlan, Colleen
    Teo, Min Yuen
    Kamradt, Jeffrey
    Khalil, Maged F.
    Ostrovnaya, Irina
    Mccoy, Asia S.
    Hettich, Grace
    Jihad, Marwah
    Folefac, Edmund
    Huang, William C.
    Bajorin, Dean F.
    Iyer, Gopa
    Bochner, Bernard H.
    Balar, Arjun Vasant
    Mortazavi, Amir
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Neoadjuvant Cohort Study in muscle-invasive Bladder Cancer (MIBC) before Cystectomy
    Rexer, Heidrun
    Boegemann, Martin
    Retz, Margitta
    AKTUELLE UROLOGIE, 2024, 55 (04) : 300 - 301
  • [37] Neoadjuvant cohort study in muscle-invasive bladder cancer (MIBC) before cystectomy
    不详
    UROLOGIE, 2024, 63 (07): : 746 - 747
  • [38] A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC)
    Xu, Abai
    Xu, Peng
    Chen, Chunxiao
    Liu, Zhe
    Jiang, Ning
    Bi, Enguang
    Cao, Manming
    Chen, BinShen
    Liu, Chunxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC)
    Satkunasivam, Raj
    Lim, Kelvin
    Teh, Bin S.
    Esnaola, Nestor F.
    Slawin, Jeremy
    Zhang, Jun
    Miles, Brian
    Brooks, Michael Austin
    Anis, Maryam
    Muhammad, Taliah
    Farach, Andrew M.
    Chen, Shu-Hsia
    Efstathiou, Eleni
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866
    Siefker-Radtke, Arlene O.
    Steinberg, Gary D.
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Moreno, Blanca Homet
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345